Canada - anglais - Health Canada

nu-pharm inc - salbutamol (salbutamol sulfate) - solution - 2mg - salbutamol (salbutamol sulfate) 2mg - selective beta 2-adrenergic agonists

Canada - anglais - Health Canada

mylan pharmaceuticals ulc - salbutamol (salbutamol sulfate) - solution - 5mg - salbutamol (salbutamol sulfate) 5mg - selective beta 2-adrenergic agonists

Australie - anglais - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - salbutamol sulfate, quantity: 120 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: oleic acid; ethanol; norflurane - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise - induced asthma or in other situations known to induce bronchospasm.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - indicated for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - indicated for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol sulfate 120.5ug;   - powder for inhalation - 100 mcg/dose - active: salbutamol sulfate 120.5ug   excipient: lactose monohydrate

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol;   - solution for injection - 0.5 mg/ml - active: salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol;   - solution for injection - 5mg/5ml - active: salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - salbutamol sulfate -